Payment overview · 2025
General Payments
$213.23
12 reported records · 8 companies
Healthcare provider profile · identity verified
Luke P Lemke, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, NE · NPI 1104820489
Verified facts
What the public records show
CMS Open Payments records show Luke P Lemke, M.D. received $213.23 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.94 | 22.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.51 | 20.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.18 | 14.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.64 | 10.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.27 | 9.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.30 | 8.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.32 | 7.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.07 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $213.23 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.80 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 307 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 115 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
307 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
307 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
115 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
293 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 989 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 836 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 835 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 616 | 145 |
| Pantoprazole Sodium | Pantoprazole Sodium | 508 | 101 |
| Omeprazole | Omeprazole | 499 | 96 |
| Losartan Potassium | Losartan Potassium | 477 | 109 |
| Metformin Hcl | Metformin Hcl | 471 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 409 | 92 |
| Lisinopril | Lisinopril | 374 | 79 |
| Ezetimibe | Ezetimibe | 362 | 98 |
| Tramadol Hcl | Tramadol Hcl | 337 | 58 |
| Gabapentin | Gabapentin | 328 | 59 |
| Jardiance | Empagliflozin | 307 | 48 |
| Eliquis | Apixaban | 293 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 260 | 45 |
| Sertraline Hcl | Sertraline Hcl | 259 | 42 |
| Allopurinol | Allopurinol | 257 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 249 | 52 |
| Simvastatin | Simvastatin | 207 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 44 |
| Warfarin Sodium | Warfarin Sodium | 196 | 19 |
| Furosemide | Furosemide | 189 | 39 |
| Carvedilol | Carvedilol | 188 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 49 |
| Trazodone Hcl | Trazodone Hcl | 178 | 31 |
| Potassium Chloride | Potassium Chloride | 176 | 32 |
| Montelukast Sodium | Montelukast Sodium | 171 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 163 | 39 |
| Farxiga | Dapagliflozin Propanediol | 153 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 30 |
| Celecoxib | Celecoxib | 142 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 22 |
| Ozempic | Semaglutide | 119 | 17 |
| Meloxicam | Meloxicam | 118 | 24 |
| Mirtazapine | Mirtazapine | 118 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 28 |
| Glimepiride | Glimepiride | 116 | 24 |
| Metformin Hcl Er | Metformin Hcl | 116 | 27 |
| Valsartan | Valsartan | 116 | 26 |
| Mounjaro | Tirzepatide | 115 | 14 |
| Irbesartan | Irbesartan | 113 | 26 |
| Spironolactone | Spironolactone | 113 | 34 |
| Nebivolol Hcl | Nebivolol Hcl | 104 | 25 |
| Famotidine | Famotidine | 103 | 20 |
| Alendronate Sodium | Alendronate Sodium | 99 | 18 |
| Myrbetriq | Mirabegron | 98 | 13 |
| Lorazepam | Lorazepam | 90 | 11 |
| Synthroid | Levothyroxine Sodium | 89 | 18 |
| Donepezil Hcl | Donepezil Hcl | 83 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 13 |
| Pregabalin | Pregabalin | 72 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 72 | 62 |
| Trulicity | Dulaglutide | 71 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 13 |
| Xarelto | Rivaroxaban | 67 | suppressed |
| Alprazolam | Alprazolam | 66 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 63 | suppressed |
| Baclofen | Baclofen | 61 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 60 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Finasteride | Finasteride | 58 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 13 |
| Prednisone | Prednisone | 56 | 20 |
| Chlorthalidone | Chlorthalidone | 54 | 12 |
| Memantine Hcl | Memantine Hcl | 54 | suppressed |
| Topiramate | Topiramate | 47 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 24 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 45 | 45 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 43 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Praluent Pen | Alirocumab | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 27 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 32 | 30 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Cholestyramine Light | Cholestyramine | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 14 |
| Levemir | Insulin Detemir | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Livalo | Pitavastatin Calcium | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Nadolol | Nadolol | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Humira | Adalimumab | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Clonidine | Clonidine | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $213.23 · 12 records | Novo Nordisk Inc | ABRYSVO, AVYCAZ, COMIRNATY, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, JARDIANCE, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, TEFLARO, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error